← Back to Search

Behavioural Intervention

Blood Pressure Management for Chronic Kidney Disease (PRESERVE Trial)

N/A

Waitlist Available

Led By Michelle Denburg, MD

Research Sponsored by Children's Hospital of Philadelphia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 18 months

Awards & highlights

PRESERVE Trial Summary

This trial will study how hypertension affects pediatric chronic kidney disease (CKD) and how to best manage BP to preserve kidney function.

Who is the study for?

This trial is for children with chronic kidney disease (CKD) who have specific levels of kidney function, measured by eGFR values between 30-89 mL/min/1.73m2. They must have had multiple tests confirming this level and seen a physician but can't join if they've had very high eGFR readings, are under 1 or over 18 years old, haven't seen a nephrologist, or already received dialysis or a kidney transplant.Check my eligibility

What is being tested?

The PRESERVE study aims to improve blood pressure management in kids with CKD to prevent further loss of kidney function. It will use data from large-scale studies to evaluate the effectiveness of consistent monitoring and treatment strategies for blood pressure and urine protein levels.See study design

What are the potential side effects?

Potential side effects may include those related to hypertension medications used in managing blood pressure. These could range from dizziness, headaches, fatigue to more serious issues depending on the medication prescribed and individual patient responses.

PRESERVE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Decline in estimated glomerular filtration rate (eGFR)

PRESERVE Trial Design

3Treatment groups

Active Control

Group I: Combined renin-angiotensin-aldosterone system (RAAS) blocker categoryActive Control1 Intervention

Secondary analyses will combine ACEi and ARB into a single RAAS blocker category.

Group II: angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) categoriesActive Control1 Intervention

The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none.

Group III: Urine protein dichotomous indicatorActive Control1 Intervention

We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Colorado, DenverOTHER

1,734 Previous Clinical Trials

2,137,799 Total Patients Enrolled

University of MiamiOTHER

900 Previous Clinical Trials

398,848 Total Patients Enrolled

Children's Hospital Medical Center, CincinnatiOTHER

815 Previous Clinical Trials

6,520,507 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment currently recruiting participants?

"Based on the information available through clinicaltrials.gov, this medical study has ceased recruitment of new patients and is no longer searching for candidates. This trial was initially listed on September 22nd 2023 before being updated on November 10th 2023; however, there are 545 other studies that are actively seeking participants at present."

Answered by AI

Does the experiment in question accept persons beyond their thirties?

"As outlined in the requirements for this experiment, adolescents aged 1 to 17 are eligible to participate."

Answered by AI

Could I be eligible to take part in this experiment?

"This medical trial is aiming to enrol 11084 children and adolescents between the ages of 1 year and 17 who have kidney disease. To qualify, patients must meet several criteria; notably they should have at least one documented visit with a physician as well as two eGFR values 30-89 mL/min/1.73m2 on different days with an interval of 90 days or more inbetween."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Preserving Kidney Function in Children With Chronic Kidney Disease

Christopher Forrest 2023. "Preserving Kidney Function in Children With Chronic Kidney Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05169411.

All > Chronic Kidney Disease > High Blood Pressure